THR Stock Overview
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ThermoGenesis Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.57 |
| 52 Week High | US$1.89 |
| 52 Week Low | US$0.30 |
| Beta | 2.39 |
| 1 Month Change | -22.45% |
| 3 Month Change | -25.97% |
| 1 Year Change | -66.07% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| THR | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.0% | -0.4% | 1.9% |
| 1Y | -66.1% | -6.0% | 5.9% |
Return vs Industry: THR underperformed the German Medical Equipment industry which returned -6.1% over the past year.
Return vs Market: THR underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| THR volatility | |
|---|---|
| THR Average Weekly Movement | 22.4% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: THR's share price has been volatile over the past 3 months.
Volatility Over Time: THR's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 25 | Chris Xu | www.thermogenesis.com |
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications.
ThermoGenesis Holdings, Inc. Fundamentals Summary
| THR fundamental statistics | |
|---|---|
| Market cap | €4.94m |
| Earnings (TTM) | -€16.66m |
| Revenue (TTM) | €8.76m |
0.6x
P/S Ratio-0.3x
P/E RatioIs THR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THR income statement (TTM) | |
|---|---|
| Revenue | US$9.45m |
| Cost of Revenue | US$7.51m |
| Gross Profit | US$1.93m |
| Other Expenses | US$19.91m |
| Earnings | -US$17.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.26 |
| Gross Margin | 20.44% |
| Net Profit Margin | -190.31% |
| Debt/Equity Ratio | -213.6% |
How did THR perform over the long term?
See historical performance and comparison